SPARC, Tripoint ink licensing pact for Elepsia XR tablets in US
"Elepsia XR can bring down the daily pill burden significantly and will be an alternative treatment option for patients suffering with epilepsy," said Anil Raghavan, CEO of SPARC.
New Delhi: Sun Pharma Advanced Research Company (SPARC) on Tuesday said it has granted exclusive licence to Tripoint Therapeutics LLC, USA, to commercialise its novel product Elepsia XR tablets in the US.
These tablets are indicated as adjunctive therapy for the treatment of partial onset seizures in patients 12 years of age and older.
"Under terms of the licence agreement, SPARC will be eligible to receive tiered royalties ranging from 15 percent to 50 percent on net sales," the company said in a statement.
SPARC said Tripoint will be responsible for all US regulatory submissions and payment of annual PDUFA (The Prescription Drug User Fee Act) fees for Elepsia XR 1,000 mg and Elepsia XR 1,500 mg.
The initial term of the agreement shall be five years and may be further extended as per mutual agreement between the parties.
"Elepsia XR can bring down the daily pill burden significantly and will be an alternative treatment option for patients suffering with epilepsy," said Anil Raghavan, CEO of SPARC.
Shares of SPARC were trading 1.66 percent higher at Rs 171.70 apiece on BSE.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.